Nagaprashantha LD et al Supplementary Fig 1



В

#1	b+	b ²⁺	b ³⁺	Seq.	y+	y ²⁺	y ³⁺	#2
1	393.23354	197.12041	131.74936	Y-TMT6plex				14
2	464.27065	232.63896	155.42840	A	1581.87326	791.44027	527.96261	13
3	521.29211	261.14970	174.43556	G	1510.83615	755.92171	504.28357	12
4	578.31358	289.66043	193.44271	G	1453.81468	727.41098	485.27641	11
5	692.35651	346.68189	231.45702	N	1396.79322	698.90025	466.26926	10
6	789.40927	395.20827	263.80794	Р	1282.75029	641.87878	428.25495	9
7	888.47768	444.74248	296.83075	V	1185.69753	593.35240	395.90403	8
8	1048.50833	524.75780	350.17430	C-Carbami	1086.62912	543.81820	362.88122	7
9	1147.57675	574.29201	383.19710	V	926.59847	463.80287	309.53767	6
10	1303.67786	652.34257	435.23080	R	827.53005	414.26866	276.51487	5
11	1400.73062	700.86895	467.58172	Р	671.42894	336.21811	224.48117	4
12	1501.77830	751.39279	501.26428	Т	574.37618	287.69173	192.13024	3
13	1598.83106	799.91917	533.61521	Р	473.32850	237.16789	158.44768	2
14				K-TMT6plex	376.27574	188.64151	126.09676	1
Fragment	Spectrum							



Α

Nagaprashantha LD et al Supplementary Fig 2



В



Α





Β

#1	b+	b ²⁺	Seq.	y+	y ²⁺	#2
1	301.20732	151.10730	A-TMT6plex			14
2	372.24444	186.62586	A	1565.77470	783.39099	13
3	485.32850	243.16789	L	1494.73759	747.87243	12
4	614.37109	307.68918	E	1381.65353	691.33040	11
5	742.42967	371.71847	Q	1252.61093	626.80910	10
6	857.45661	429.23195	D	1124.55236	562.77982	9
7	970.54068	485.77398	L	1009.52541	505.26634	8
8	1041.57779	521.29253	A	896.44135	448.72431	7
9	1188.64621	594.82674	F	825.40423	413.20576	6
10	1374.72552	687.86640	W	678.33582	339.67155	5
11	1537.78885	769.39806	Y	492.25651	246.63189	4
12	1594.81031	797.90879	G	329.19318	165.10023	3
13	1691.86307	846.43518	Р	272.17172	136.58950	2
14			R	175.11895	88.06311	1

Fragment Spectrum

rm171114ol081.raw #45761_RT: 109.6678 min ITMS, 933.4915@cid35.00, z=+2, Mono m/z=933.49146 Da, MH+=1865.97563 Da, Match Tol.=0.6 Da









В



Nagaprashantha LD et al Supplementary Fig 5









Supplemental Figure Legends:

Supplemental Figure S1: Identification of the non-phosphorylated protein PCNA associated isoform 1 (PAF1) peptide YAGGNPVCVRPTTPK: *A*, The PAF1 protein showing the sequence coverage following TMT 10plex MS/MS analyses in breast cancer cells. *B*, The MS/MS spectrum obtained by Proteome Discoverer 2.2 software corresponding to PAF1 peptide YAGGNPVCVRPTTPK. The MS/MS spectra were extracted and searched using Thermo Proteome Discoverer 2.2/Sequest HT against the NCBI Homo Sapiens Reference Sequences database.

Supplemental Figure S2: Identification of the non-phosphorylated protein ribonucleotide reductase M2 subunit (RRM2) peptide GLMPGLTFSNELISR: *A*, The RRM2 protein showing the sequence coverage following TMT 10plex MS/MS analyses in breast cancer cells. *B*, The MS/MS spectrum obtained by Proteome Discoverer 2.2 software corresponding to RRM2 peptide GLMPGLTFSNELISRAKR. The MS/MS spectra were extracted and searched using Thermo Proteome Discoverer 2.2/Sequest HT against the NCBI Homo Sapiens Reference Sequences database.

Supplemental Figure S3: Identification of the non-phosphorylated protein Heme Oxygenase 1 (HO1) peptide AALEQDLAFWYGPR: *A*, The HO1 protein showing the sequence coverage following TMT 10plex MS/MS analyses in BC cells. *B*, The MS/MS spectrum obtained by Proteome Discoverer 2.2 software corresponding to HO1 peptide AALEQDLAFWYGPR. The MS/MS spectra were extracted and searched using Thermo Proteome Discoverer 2.2/Sequest HT against the NCBI Homo Sapiens Reference Sequences database.

Supplemental Figure S4: Identification of the phosphoprotein ubiquitin fusion degradation protein 1 (UFD1) peptide AFSGp-SGNRLDGK: *A*, The UFD1 protein showing the sequence coverage following TMT 10plex MS/MS analyses in BC cells. *B*, The MS/MS spectrum obtained by Proteome Discoverer 2.2 software corresponding to UFD1 phosphopeptide AFSGp-SGNRLDGK. The MS/MS spectra were extracted and searched using Thermo Proteome Discoverer 2.2/Sequest HT against the NCBI Homo Sapiens Reference Sequences database.

Supplemental Figure S5: Effect of 2HF on Small Molecule Biochemistry Network in MCF7 cells. Ingenuity Pathway Analyses (IPA) revealing the regulation of small molecule biochemistry network and associated proteins including 60S ribosomal subunit, DDX56, RPL10A, HIST1H1E, PDCD11 and HMOX2 in MCF7 breast cancer cells.

Supplemental Figure S6: Effect of 2HF on Cell Cycle Network in MCF7 cells. Ingenuity Pathway Analyses (IPA) revealing the regulation of cell cycle and associated proteins including HIST1HC, Top2, DEK, KLF16 and NCAPD3 in MCF7 breast cancer cells.

Supplemental Figure S7: Effect of 2HF on MITF Network in MDA-MB231 cells. Ingenuity Pathway Analyses (IPA) revealing the regulation of MITF network and associated proteins including CDK2, UBE2C, NCAPD3 and SDC1 in MDA-MB231 breast cancer cells.

Supplemental Figure S8: Effect of 2HF on FGF7 Network in MDA-MB231 cells. Ingenuity Pathway Analyses (IPA) revealing the regulation of FGF7 network and associated proteins including CDK4, CDK2, CAD and LPCAT1 in MDA-MB231 breast cancer cells.